The companies will focus initially on accelerating first-in-human clinical studies on up to three small molecule compounds developed by Senda
Senda Biosciences, a US based therapeutics platform company creating novel categories of medicines based on a new field of science called Intersystems Biology, recently entered into a strategic collaboration with Nestlé Health Science for the development of novel nutritional therapies for a wide range of metabolic conditions, including obesity and glycemia.
The companies will focus initially on accelerating first-in-human clinical studies on up to three small molecule compounds developed by Senda, leveraging the capabilities of Nestlé Health Science, a global leader in the science of nutrition. The compounds have been rationally designed based on Senda’s Intersystems Biology discovery platform and screened through Senda’s proprietary bioassays for their potential to improve metabolic health.
In preclinical studies these compounds have shown the ability to achieve sustained reductions in weight, as well as improvements in glucose clearance and liver health.
Senda’s Intersystems Biology discovery platform combines an extensive human sampling of previously uncharted tissues with advanced computational biology to generate novel, actionable insights into the trillions of interspecies molecular connections in the human body. It harnesses the power of this pharmacy within us to develop novel pharmacological and nutritional approaches.
Under the terms of the agreement, the two companies will collaborate on the development and commercialization of these compounds for metabolic health, with Senda granting Nestlé Health Science exclusive global commercialization rights in the nutritional field. The agreement also enables further collaboration on the development of a prescription therapeutic, with Senda retaining therapeutic ownership rights.